NYSEMKT: CLDI
Calidi Biotherapeutics Inc Stock Ownership - Who owns Calidi Biotherapeutics?

Insider buying vs selling

Have Calidi Biotherapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Allan CamaisaDirector2025-12-12850$1.46
$1.24kSell

1 of 1

CLDI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CLDI insiders and whales buy or sell their stock.

CLDI Shareholders

What type of owners hold Calidi Biotherapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Allan Camaisa349.92%9,042,620$12.21MInsider
First Light Acquisition Group LLC74.76%1,931,852$2.61MInsider
Polar Asset Management Partners Inc33.35%861,800$1.16MInsider
Lincoln Alternative Strategies LLC28.25%730,000$985.50kInsider
Thomas A. Vecchiolla27.43%708,792$956.87kInsider
Stephen Thesing18.25%471,544$636.58kInsider
Boris Radoslavov Minev16.43%424,458$573.02kInsider
Santidrian Antonio Fernandez12.68%327,788$442.51kInsider
Scott Leftwich11.75%303,711$410.01kInsider
Tony T. Kalajian10.79%278,790$376.37kInsider

1 of 3

CLDI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CLDI0.00%100.00%Net Selling
GOVX0.00%100.00%Net Buying
ADXN0.00%18.65%
BRTX0.00%100.00%Net Buying
PPBT0.00%1.89%

Calidi Biotherapeutics Stock Ownership FAQ

Who owns Calidi Biotherapeutics?

Calidi Biotherapeutics (NYSEMKT: CLDI) is owned by 0.02% institutional shareholders, 612.98% Calidi Biotherapeutics insiders, and 0.00% retail investors. Allan Camaisa is the largest individual Calidi Biotherapeutics shareholder, owning 9.04M shares representing 349.92% of the company. Allan Camaisa's Calidi Biotherapeutics shares are currently valued at $12.52M.

If you're new to stock investing, here's how to buy Calidi Biotherapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.